Denosumab Administration After Spinal Cord Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01983475

Recruitment Status : Unknown

Verified March 2019 by William A. Bauman, M.D., James J. Peters Veterans Affairs Medical Center.
Recruitment status was: Recruiting

First Posted : November 14, 2013

Last Update Posted : March 8, 2019

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Kessler Institute for Rehabilitation

Information provided by (Responsible Party):

William A. Bauman, M.D., James J. Peters Veterans Affairs Medical Center

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	May 2020
Estimated Study Completion Date :	May 2020

Publications:

Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW; Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010 Oct;25(10):2256-65. doi: 10.1002/jbmr.149.

Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716.

To Top